Rhythm Pharmaceuticals, Inc. (RYTM)
111.44
+1.44
(+1.31%)
USD |
NASDAQ |
Aug 24, 16:00
111.41
-0.03
(-0.03%)
After-Hours: 20:00
Rhythm Pharmaceuticals Net Income (Quarterly) : -49.30M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -49.30M |
| March 31, 2026 | -55.64M |
| December 31, 2025 | -47.50M |
| September 30, 2025 | -52.90M |
| June 30, 2025 | -46.63M |
| March 31, 2025 | -49.50M |
| December 31, 2024 | -43.29M |
| September 30, 2024 | -43.64M |
| June 30, 2024 | -32.26M |
| March 31, 2024 | -141.37M |
| December 31, 2023 | -41.62M |
| September 30, 2023 | -44.16M |
| June 30, 2023 | -46.70M |
| March 31, 2023 | -52.18M |
| December 31, 2022 | -42.49M |
| September 30, 2022 | -40.86M |
| June 30, 2022 | -45.00M |
| March 31, 2022 | -52.76M |
| December 31, 2021 | -42.87M |
| September 30, 2021 | -35.11M |
| June 30, 2021 | -35.39M |
| March 31, 2021 | 43.75M |
| December 31, 2020 | -34.90M |
| September 30, 2020 | -33.82M |
| June 30, 2020 | -31.12M |
| Date | Value |
|---|---|
| March 31, 2020 | -34.16M |
| December 31, 2019 | -32.96M |
| September 30, 2019 | -36.00M |
| June 30, 2019 | -42.80M |
| March 31, 2019 | -28.97M |
| December 31, 2018 | -25.51M |
| September 30, 2018 | -17.69M |
| June 30, 2018 | -14.41M |
| March 31, 2018 | -16.46M |
| December 31, 2017 | -10.62M |
| September 30, 2017 | -11.43M |
| June 30, 2017 | -8.008M |
| March 31, 2017 | -7.526M |
| September 30, 2016 | -7.191M |
| June 30, 2016 | -6.528M |
| March 31, 2016 | -6.183M |
| December 31, 2015 | -6.752M |
| September 30, 2015 | -3.12M |
| December 31, 2014 | -0.762M |
| September 30, 2014 | -0.246M |
| June 30, 2014 | -3.435M |
| March 31, 2014 | -3.533M |
| June 30, 2013 | -6.344M |
| March 31, 2013 | -4.477M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Aprea Therapeutics, Inc. | -3.591M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 71.26M |
| Total Expenses (Quarterly) | 120.55M |
| EPS Diluted (Quarterly) | -0.7342 |
| Enterprise Value | 7.562B |
| Gross Profit Margin (Quarterly) | 87.39% |
| Profit Margin (Quarterly) | -69.19% |
| Earnings Yield | -2.80% |
| Normalized Earnings Yield | -2.788 |